
Neurologist

No OPD information available
Becker Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary Lateral Sclerosis
Riboflavin Transporter Deficiency Neuronopathy
Cramp-Fasciculation Syndrome
Facioscapulohumeral Muscular Dystrophy (FSHD)
Infantile Axonal Neuropathy
Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy Type 2
Spinal Muscular Atrophy Type 3
Ian R. Woodcock is a male healthcare provider who specializes in helping patients with various muscle and nerve conditions. Some of the conditions he works with include Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, and Spinal Muscular Atrophy. He also helps patients with other conditions like Primary Lateral Sclerosis and Facioscapulohumeral Muscular Dystrophy.
Ian R. Woodcock uses special skills and treatments to help his patients feel better. He is very good at communicating with his patients, which makes them trust him. Patients feel comfortable talking to him about their health concerns.
To make sure he is giving the best care, Ian R. Woodcock stays up-to-date with the latest medical knowledge and research. This helps him provide the most effective treatments for his patients. He also works closely with other medical professionals to share knowledge and improve patient care.
Ian R. Woodcock's work has had a positive impact on many patients' lives. He has published research in medical journals, like "A contemporary analysis of the Australian clinical and genetic landscape of spinal muscular atrophy," which helps other healthcare providers learn from his findings. He is also involved in clinical trials to test new treatments for conditions like Duchenne Muscular Dystrophy.
In summary, Ian R. Woodcock is a caring and knowledgeable healthcare provider who uses his expertise to help patients with muscle and nerve conditions. He stays informed about the latest research, collaborates with other professionals, and works to improve the lives of those he treats.
Enrollment Status: Active not recruiting
Published: December 16, 2024
Intervention Type: Drug
Study Drug:
Study Phase: Phase 3
